Table 3.
Treatment | %G | %NG | %EL | %EM | %Viable | %Non-viable | %RG | E:S ratio (± SE) |
---|---|---|---|---|---|---|---|---|
1 | 7.1 | 14.3 | 28.6 | 50.0 | 21.4 | 78.6 | 33.3 | 0.51 (± 0.25) |
2 | 27.3 | 0.0 | 45.5 | 27.3 | 27.3 | 72.7 | 100.0 | 1.00 (± 0.00)* |
3 | 22.2 | 33.3 | 0.0 | 44.4 | 55.6 | 44.4 | 40.0 | 0.50 (± 0.21) |
4 | 17.8 | 2.2 | 11.1 | 68.9 | 20.0 | 80.0 | 88.9 | 0.98 (± 0.02)* |
5 | 12.8 | 10.3 | 23.1 | 53.8 | 23.1 | 76.9 | 55.6 | 0.71 (± 0.13)* |
6 | 16.0 | 12.0 | 8.0 | 64.0 | 28.0 | 72.0 | 57.1 | 0.74 (± 0.14)* |
7 | 13.6 | 27.3 | 8.0 | 51.1 | 40.9 | 59.1 | 33.3 | 0.54 (± 0.06)* |
8 | 22.2 | 20.8 | 15.3 | 41.7 | 43.1 | 56.9 | 51.6 | 0.68 (± 0.06)* |
9 | 15.1 | 19.2 | 19.2 | 46.6 | 34.2 | 65.8 | 44.0 | 0.62 (± 0.07)* |
10 | 5.4 | 39.5 | 34.0 | 21.1 | 44.9 | 55.1 | 12.1 | 0.48 (± 0.05)* |
11 | 3.3 | 36.7 | 34.0 | 26.0 | 40.0 | 60.0 | 8.3 | 0.47 (± 0.05)* |
12 | 1.3 | 34.2 | 36.2 | 28.2 | 35.6 | 64.4 | 3.8 | 0.43 (± 0.04)* |
13 | 4.0 | 28.7 | 20.7 | 46.7 | 32.7 | 67.3 | 12.2 | 0.57 (± 0.08)* |
14 | 2.1 | 37.6 | 27.0 | 33.3 | 39.7 | 60.3 | 5.4 | 0.43 (± 0.04)* |
15 | 5.0 | 43.3 | 22.7 | 29.1 | 48.2 | 51.8 | 10.3 | 0.45 (± 0.04)* |
16 | 4.8 | 32.9 | 29.5 | 32.9 | 37.7 | 62.3 | 12.7 | 0.49 (± 0.06)* |
17 | 2.8 | 40.0 | 27.6 | 29.7 | 42.8 | 57.2 | 6.5 | 0.42 (± 0.04)* |
18 | 0.0 | 35.7 | 32.2 | 32.2 | 35.7 | 64.3 | 0.0 | 0.36 (± 0.02) |
19 | 0.0 | 38.5 | 29.4 | 32.2 | 38.5 | 61.5 | 0.0 | 0.33 (± 0.01) |
20 | 0.0 | 42.8 | 26.9 | 30.3 | 42.8 | 57.2 | 0.0 | 0.35 (± 0.01) |
21 | 0.0 | 42.4 | 32.6 | 25.0 | 42.4 | 57.6 | 0.0 | 0.36 (± 0.01)* |
22 | 2.3 | 32.6 | 28.0 | 37.1 | 34.9 | 65.1 | 6.6 | 0.45 (± 0.06)* |
23 | 1.7 | 28.2 | 31.6 | 38.5 | 29.9 | 70.1 | 5.8 | 0.49 (± 0.08)* |
24 | 1.1 | 39.5 | 29.4 | 29.9 | 40.7 | 59.3 | 2.8 | 0.37 (± 0.03) |
25 | 0.0 | 41.7 | 30.3 | 28.0 | 41.7 | 58.3 | 0.0 | 0.37 (± 0.01)* |
26 | 1.7 | 41.0 | 28.3 | 28.9 | 42.8 | 57.2 | 4.1 | 0.40 (± 0.04)* |
27 | 1.1 | 45.4 | 30.5 | 23.0 | 46.6 | 53.4 | 2.5 | 0.37 (± 0.03) |
Mean | 7.1 | 30.4 | 25.5 | 37.0 | 37.4 | 62.6 | 22.1 | 0.51 (± 0.03) |
Treatment with E:S different significantly with control (0.31) at p < 0.05 is indicated (*).